Claudin-10 (CLDN10) has been reported to be upregulated in papillary thyroid cancer and KRAS mutant non-squamous cell lung cancer and reduced in clear cell renal cell carcinoma [22,138,139,140]. Here, KRAS is linked to clear cell renal carcinoma.